EA202190862A1 - Способы лечения - Google Patents

Способы лечения

Info

Publication number
EA202190862A1
EA202190862A1 EA202190862A EA202190862A EA202190862A1 EA 202190862 A1 EA202190862 A1 EA 202190862A1 EA 202190862 A EA202190862 A EA 202190862A EA 202190862 A EA202190862 A EA 202190862A EA 202190862 A1 EA202190862 A1 EA 202190862A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treatment
cancer
compositions
tumor antigens
Prior art date
Application number
EA202190862A
Other languages
English (en)
Inventor
Джессика Бейкер Флехтнер
Мари Лосски-Элайас
Памела М. Кэрролл
Хуберт Лэм
Лиза К. Макнил
Венди Джейн Брум
Original Assignee
Геноцеа Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Геноцеа Байосайенсиз, Инк. filed Critical Геноцеа Байосайенсиз, Инк.
Publication of EA202190862A1 publication Critical patent/EA202190862A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данном документе предложены способы и композиции для идентификации опухолевых антигенов лимфоцитов человека и для лечения субъектов, имеющих рак.
EA202190862A 2018-09-27 2019-09-27 Способы лечения EA202190862A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737862P 2018-09-27 2018-09-27
PCT/US2019/053669 WO2020069452A1 (en) 2018-09-27 2019-09-27 Treatment methods

Publications (1)

Publication Number Publication Date
EA202190862A1 true EA202190862A1 (ru) 2021-07-07

Family

ID=69953226

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190862A EA202190862A1 (ru) 2018-09-27 2019-09-27 Способы лечения

Country Status (14)

Country Link
US (1) US20230041057A1 (ru)
EP (1) EP3856207A4 (ru)
JP (1) JP2022502433A (ru)
KR (1) KR20210091137A (ru)
CN (1) CN113194967A (ru)
AU (1) AU2019351273A1 (ru)
BR (1) BR112021005596A2 (ru)
CA (1) CA3113259A1 (ru)
CO (1) CO2021005207A2 (ru)
EA (1) EA202190862A1 (ru)
IL (1) IL281792A (ru)
MX (1) MX2021003262A (ru)
SG (1) SG11202102878TA (ru)
WO (1) WO2020069452A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
WO2021108727A1 (en) * 2019-11-27 2021-06-03 Myst Therapeutics, Inc. Method of producing tumor-reactive t cell composition using modulatory agents
CN113278731A (zh) * 2021-05-12 2021-08-20 广西医科大学 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) * 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
CN1902488A (zh) * 2003-11-13 2007-01-24 健泰科生物技术公司 肿瘤治疗的筛选实验和方法
EP3363907A1 (en) * 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
ES2672895T3 (es) * 2005-08-05 2018-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generación de células T específicas de antígeno
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
EP3102233A4 (en) * 2014-02-05 2017-11-22 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
TWI742008B (zh) * 2015-11-02 2021-10-11 美商健生生物科技公司 使用特異性結合ｃｄ３８之抗體免疫調節及治療固態腫瘤

Also Published As

Publication number Publication date
CA3113259A1 (en) 2020-04-02
JP2022502433A (ja) 2022-01-11
CN113194967A (zh) 2021-07-30
CO2021005207A2 (es) 2021-07-30
KR20210091137A (ko) 2021-07-21
US20230041057A1 (en) 2023-02-09
AU2019351273A1 (en) 2021-05-20
EP3856207A4 (en) 2022-11-16
EP3856207A1 (en) 2021-08-04
SG11202102878TA (en) 2021-04-29
IL281792A (en) 2021-05-31
BR112021005596A2 (pt) 2021-06-29
MX2021003262A (es) 2021-07-15
WO2020069452A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2019011148A (es) Metodos de tratamiento.
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
EA201691487A1 (ru) Антитела человека к pd-l1
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA202190862A1 (ru) Способы лечения
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
CO2021005234A2 (es) Métodos de tratamiento
EA202192400A1 (ru) Антитела против интегрина и их применение
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
EA202190856A1 (ru) Способы лечения
EA201890014A1 (ru) Терапевтические композиции, содержащие дипиридамол, наборы для лечения, содержащие эти композиции, и способы их производства